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The hallmark of the multidrug resistance (MDR) phenotype is
resistance of tumour cells to a variety of structurally diverse cyto-
toxic drugs, mainly natural products such as anthracyclines, vinca
alkaloids, and taxanes (Bradley et al, 1988). One important
mechanism of MDR involves cell membrane transporters such as
P-glycoprotein (Pgp) (Bradley et al, 1988) and multidrug resis-
tance-associated protein (MRP) (Cole et al, 1992), which function
as drug-efflux pumps and keep cytotoxic drugs out of cells. Gene-
transfection studies have confirmed the role of Pgp and MRP in
MDR (Bradley et al, 1988; Belli et al, 1990; Fairchild et al, 1990;
Brueninger et al, 1995) and an association has been shown
between Pgp and/or MRP overexpression and clinical refractori-
ness in a variety of cancers (Chan et al, 1988; Kuwazuru et al,
1990; Schuurhuis et al, 1995), though high drug-resistance factors
do not necessarily reflect clinical resistance. 
Pgp-mediated MDR can be reversed in vitro by a variety of
compounds which inhibit Pgp function and allow greater concen-
trations of chemotherapeutic drugs to be achieved intracellularly
(Ford and Hait, 1990). Among the first-generation Pgp modulators
are cyclosporin A, verapamil, and quinidine. In early attempts at
modulation of Pgp function in the clinic with these drugs, the
results were generally unsuccessful. This has been attributed to
poor selection of patients, inadequate concentrations of modulator
reaching solid tumours, and pharmacokinetic interactions between
modulators and cytotoxic drugs leading to enhanced toxicity
(Tunggal et al, 1999). Identification of structural features necessary
for anti-Pgp activity has allowed the design of more specific and
potent second-generation modulators, such as GG918 (elacridar)
(Hyafil et al, 1993), PSC833 (valspodar) (Twentyman, 1988), and
LY335979 (Dantzig et al, 1996), which are undergoing clinical
study. 
It is often difficult to determine whether an individual patient’s
tumour overexpresses Pgp. One method applied clinically is flow
cytometry, in which cellular fluorescence intensity serves as an
indicator of accumulation of a fluorescent Pgp substrate, such as
doxorubicin or rhodamine-123, which is inversely correlated with
Pgp efflux function. It therefore provides a rapid estimation of
the cellular dynamics of drug accumulation and efflux, making
possible timely modifications in treatment regimens and mon-
itoring drug resistance (Kessel et al, 1991). The assay is quick and
requires only a small sample (10 000 to 20 000 cells) for mean-
ingful analysis. Although this is simple in cell lines, application to
cells from primary tumours presents problems of tumour cell
heterogeneity, contamination with host cells, and limitations in
obtaining biopsy samples. Flow cytometry has therefore been
most successfully applied to haematological malignancies, lymph-
omas and relatively few solid tumours (Xie et al, 1995). 
A newer application in studies of Pgp function is the use
of radionuclide imaging. Technetium-99m-labelled sestamibi, a
lipophilic cationic radiopharmaceutical approved for clinical use
in myocardial perfusion imaging and breast cancer detection, has
been used for a number of years for imaging tumours. The obser-
vation that variable accumulation in cell lines in vitro was due to
sestamibi being a transport substrate for Pgp led to further explor-
ation of sestamibi for application in MDR (Piwnica-Worms et al,
1993). As a transport substrate, sestamibi levels show an inverse
correlation with Pgp expression (Del Vecchio et al, 1997).
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lators of Pgp function, have been studied in vitro, in animal
models, and extended to the clinic (Del Vecchio et al, 1999;
Hendrikse et al, 1999). 
Because of the combined potential of sestamibi imaging and
doxorubicin flow cytometry to assess Pgp function, we undertook
a comparison of the two methods in the same in vitro system in
order to determine the relationship between their results and to
assess the diagnostic and predictive value of sestamibi imaging.
For the present study, a human breast cancer cell line was chosen
because MDR is a common problem in breast cancer (Trock et al,
1997), sestamibi imaging has been applied in this type of cancer
(Del Vecchio et al, 1997), and both drug-selected MCF7/AdrR and
MDRI-gene-transfected MCF7/BC19 variants of the human breast
cancer cell line MCF7/WT were available (Batist et al, 1986;
Fairchild et al, 1990). These variants were included to separate the
effects of Pgp alone (MCF7/BC19) in MDR from the collective
effects of other factors (MCF7/AdrR) associated with MDR pheno-
mena. The effects of the potent second-generation Pgp modulators
GG918 and PSC833 were studied on accumulation of both agents
and on doxorubicin cytotoxicity in resistant cells. 
MATERIALS AND METHODS 
Cell culture 
The sensitive MCF7/WT cell line was obtained from the American
Type Culture Collection (Rockville, MD). The doxorubicin-
selected resistant cell line MCF7/AdrR was provided by Dr
G Batist (McGill University, Montreal, QC) (Batist et al, 1986)
and the MDRI-transfected MCF7/BC19 was developed by Dr
C Fairchild (Fairchild et al, 1990) and provided by Dr W Hait
(Cancer Institute of New Jersey, Piscataway, NJ). The MDRI gene
isolated from MCF7/AdrR cells had been used to transfect
MCF7/WF cells to generate the MCF7/BC19 cell line, which
showed a pattern of resistance similar to MCF7/AdrR cells
(Fairchild et al, 1990). The resistance to doxorubicin in
MCF7/AdrR and MCF7/BC19 cells was 192-fold (Batist et al,
1986) and 14-fold (Fairchild et al, 1990) relative to MCF7/WT
cells. The colchicine-resistant Chinese hamster ovary cell line
CHR-C5 was provided by Dr V Ling (British Columbia Cancer
Agency, Vancouver, BC) as a positive control. 
Alpha minimum essential medium (a-MEM) was used for all
cell lines except MCF7/BC19 which was grown in RPMI-1640.
Media were supplemented with 10% fetal bovine serum and the
antibiotics penicillin (100 IU ml—1)and streptomycin (100mg ml–1).
Cells were grown at 37˚C in a humidified atmosphere of 5%
CO2/95% air. Single-cell suspensions at 1 ´ 106 cells ml–1 were
prepared by trypsinization (0.1% Bacto trypsin, Difco Labs) and
cells were counted using an electronic particle counter (ZM
system, Coulter Electronics Ltd, Bedfordshire, UK). 
Reagents and chemicals 
Sestamibi was prepared by addition of 99mTc-pertechnetate to kits
(Dupont Pharma, Billerica, MA) and boiling for 15 min. Labelling
efficiency, determined by instant thin-layer chromatography, was
always above 90%. Sestamibi was diluted to 10 MBq ml–1 in saline
prior to addition to the cell preparation. Stock solutions were
prepared as follows: doxorubicin (Abbott Laboratories, North
Chicago, IL) 0.74 mM in PBS, stored at –20˚C; GG918 
(Glaxo-Wellcome, Research Triangle, NC) 1 mM in methanol/0.1
N hydrochloric acid (4:1), freshly diluted to the required concen-
tration with a-MEM; PSC833 (Novartis Pharmaceuticals, East
Hanover, NJ) 1 mM in absolute ethanol, freshly diluted in absolute
ethanol. 
The primary C219 antibody (1 mg ml–1) was a gift from Dr
V Ling (British Columbia Cancer Agency, Vancouver) and
secondary anti-mouse IgG and all reagents for Western blotting
were purchased from Sigma Chemicals. 
99mTc-sestamibi accumulation 
The experimental protocol was same as reported previously by our
group (Ballinger et al, 1995, 1996, 1997; Muzzammil et al, 1999).
Briefly, single-cell suspensions at 1 ´ 106 cells ml–1 were incubated
with stirring in a 37˚C water bath for 5 min to allow equilibration.
Appropriate concentrations of modulator (0.01 to 0.2mM GG918
and 0.05 to 2.0 mM PSC833) were then added and incubated for 15
min. Sestamibi was added at a final concentration of 0.1 MBq ml–1
and samples were taken after 0.5, 15, 30, 45 and 60 min. Duplicate
aliquots of 500 ml were transferred into 1.5-ml microcentrifuge
tubes containing 500 ml ice-cold PBS, centrifuged for 2 min at
14 000 g in a refrigerated microcentrifuge, and the pellets were
washed carefully with ice-cold saline. The supernatant was aspir-
ated and the tips of the tubes containing the pellets were clipped
into gamma counting tubes and assayed for radioactivity in a
gamma well counter along with an appropriate standard. The accu-
mulation ratio was calculated as the ratio of activity concentration
inside the cell to that outside (Cin/Cout) in an equal volume of
supernatant medium using an independent measurement of cell
volume as described previously (Ballinger et al, 1995). 
Doxorubicin flow cytometry 
Cell concentrations, modulator drug concentrations, incubation
times, and sampling times were exactly the same as in the above
experiments. Addition of doxorubicin at a final concentration of
5.5 mM defined time zero. At each time point, samples were
poured into cytometry tubes containing ice-cold PBS, kept on ice
and filtered through a nylon sieve before measurements to ensure
single-cell analysis. Cell-associated doxorubicin fluorescence was
determined with an EPICS-XL-MCL flow cytometer (Coulter
Electronics). For calibration, instrument response was checked
before each batch of sample measurements by standard DNA-
check beads (Coulter). Fluorescence was excited at 488 nm and
emission wavelengths between 550 and 600 nm were detected
with a 575-nm band pass filter. Information was collected for
10 000 cells in a gated region at 100 to 300 cells s–1.Mean doxo-
rubicin fluorescence associated with cells was analysed from
single histograms of relative fluorescence intensity and two-
dimensional contours of forward scatter and 90˚ scatter. Results
were presented as mean fluorescence and autofluorescence was
subtracted from each measurement before analysis.
Western blot analysis and immunohistochemical
staining 
Membrane preparations made from the three MCF7 variants and
CHR-C5 were immunoblotted with the mouse monoclonal
primary antibody C219 directed against Pgp, followed by a
horseradish-peroxidase-conjugated secondary antibody which was
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using a computing densitometer and the density-to-amount of
protein relationship determined for CHR-C5 cell line was used to
express the relative Pgp content in each cell line. 
Cytospin slides were prepared at a concentration of 1 ´ 106 cells
ml–1 and stained for Pgp using the JSB-1 primary antibody.
Cytotoxicity assays 
For each cell line, 1 ´ 105 cells were cultured in T25 tissue culture
flasks 10 to 12 h prior to addition of any drugs. Attached cells were
incubated with 2 mM PSC833 for 15 min before addition of
doxorubicin at 1.8 and 5.5 mM. After 1- and 4-h incubations, cells
were trypsinized and seeded at 200 to 12 000 cells per 60-mm
tissue culture plate, depending on doxorubicin concentration,
modulator treatment, cell line variant, and incubation time.
Colonies were allowed to develop for 10 to 12 days and results
were determined as percent survival of colonies developing under
doxorubicin/PSC833-treated conditions relative to controls. 
RESULTS 
In vitro studies of sestamibi accumulation and effects
of Pgp modulators 
The time course of accumulation of sestamibi in wild-type and
resistant variants of MCF7 cells under control conditions is shown
in Figure 1A. Cellular uptake of sestamibi was continuous and
accumulation ratios of 40.5 ± 6.7 (mean ± SD) in MCF7/WT cells,
3.92 ± 0.37 in MCF7/BC19 cells, and 0.64 ± 0.02 in MCF7/AdrR
cells (n = 3) were seen at the end of 60 min, which indicates much
higher activity concentration inside cells than in the surrounding
medium. The percent uptakes relative to MCF7/WT cells were
therefore 9.7% in MCF7/BC19 cells and 1.6% in MCF7/AdrR
cells, and the two resistant cell lines showed a 6-fold difference in
their sestamibi uptake. A plateau was achieved in both resistant
cell lines by 30 min while in MCF7/WT cells the rate of accumu-
lation had decreased by 60 min but no plateau was evident.
Addition of a Pgp modulator caused dose-dependent inhibition
of Pgp-efflux function and increased tracer accumulation to a
different extent in both resistant cell lines. In MCF7/BC19 cells,
0.01 mM GG918 and 2.0 mM PSC833 restored sestamibi accumu-
lation to MCF7/WT levels and the shape of the accumulation
curves became similar to MCF7/WT controls (Figures 2A and 2B).
In MCF7/AdrR cells, the same doses of both modulators caused
only partial reversal of Pgp-efflux function and restored 29%
to 34% of sestamibi levels seen in MCF7/WT cells (Figures 2C
and 2D). A modest effect (<20%) of modulators was seen in
MCF7/WT cells. EC50 for restoration of sestamibi accumulation
was <0.05 mM for GG918 and <0.05 mM for PSC833. For
PSC833, the maximum effect on Pgp reversal was seen by 30 min
at all concentrations, after which there was a decline. For GG918,
the effect was continuous over 60 min and its relative potency with
respect to PSC833 was 10-fold. 
In vitro studies of doxorubicin accumulation and
effects of Pgp modulators 
The time course of accumulation of doxorubicin in wild-type and
resistant cells under control conditions is shown in Figure 1B.
Doxorubicin uptake in cells continued over the 60-min time course
and mean fluorescence values were 10.86 ± 0.88 for MCF7/WT
cells, 6.46 ± 1.66 for MCF7/BC19 cells, and 3.12 ± 0.66 for
MCF7/AdrR cells (n = 3) at the end of incubation. Percent uptakes
relative to MCF7/WT cells were therefore 59% in MCF7/BC19
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Figure 1 Accumulation of sestamibi (panel A) and doxorubicin (panel B) in
MCF7/WT, MCF7/BC19, and MCF7/AdrR cells in vitro as a function of time.
Each point is the mean ± SD of 3 independent experiments. Where error
bars are not shown, SD is smaller than the size of the symbol 
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Figure 2 Effects of addition of modulators GG918 (panels A and C) and
PSC833 (panels B and D) on sestamibi accumulation in resistant variants
MCF7/BC19 (panels A and B) and MCF7/AdrR (panels C and D) cells.
Results are expressed as % of 60-min accumulation levels in MCF7/WT
cells. Each point is the mean of 3 independent experiments and the average
SD is 20% of the mean and 29% in MCF7/AdrR cells, and the two resistant cells showed a
2-fold difference in their doxorubicin uptake. In MCF7/BC19
cells, an increase in doxorubicin uptake to MCF7/WT levels was
seen with 0.2 mM GG918 and 0.1 mM PSC833 (Figures 3A and 3B),
while in MCF7/AdrR cells, similar effects were seen with 0.05 mM
GG918 and 1.0 mM PSC833 (Figures 3C and 3D). Modulator
dose–response curves indicated EC50 values (0.05 mM) for doxoru-
bicin uptake which were lower than was observed for sestamibi.
Unlike sestamibi, no significant effects of modulators were seen in
MCF7/WT cells. 
Western blot and immunohistochemical analysis of 
P-glycoprotein in cells 
Analysis of 1- to 20-mg membrane protein samples from the CHR-
C5 cell line showed a linear relationship up to 10 mg protein with a
correlation coefficient of 0.96. From this standard curve, the Pgp
content was calculated for 10-mg membrane protein samples from
each of the cell-line variants. The Pgp expression in MCF7/BC19
and MCF7/AdrR cells was not significantly different at 3.42 ±
1.67 and 4.06 ± 1.86 mg, respectively (n = 3), and no detectable
Pgp expression was observed in MCF7/WT cells. Staining for Pgp
with the monoclonal antibody JSB-1 showed heterogeneous
expression of this protein in MCF7/BC19 cells and a more
uniform expression in MCF7/AdrR cells (data not shown).
MCF7/AdrR cells, however, showed evidence of other morpho-
logical changes, as reported previously (Sommers et al, 1994). 
Cytotoxicity assay 
Figure 4 demonstrates that MCF7/BC19 and MCF7/AdrR cells
(open symbols) were highly resistant to doxorubicin in compar-
ison to MCF7/WT cells, but that addition of 2 mM PSC833 (closed
symbols) enhanced the cytotoxicity of doxorubicin 3- to 30-fold in
the resistant cell lines. Although the results in Figure 3 show that
2 mM PSC833 results in equivalent concentrations of doxorubicin
in MCF7/BC19 and MCF7/AdrR cells, Figure 4 suggests a differ-
ence in cytotoxicity of 2- to 5-fold. 
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Figure 3 Effects of addition of modulators GG918 (panels A and C) and
PSC833 (panels B and D) on doxorubicin accumulation in resistant variants
MCF7/BC19 (panels A and B) and MCF7/AdrR (panels C and D) cells.
Results are expressed as % of 60-min accumulation levels in MCF7/WT
cells. Each point is the mean of 3 independent experiments and the average
SD is 37% of the mean
100
10
1 
 0
100
10
1 
 0
100
10
1 
 0
024 024 024
1.8 mM
control
1.8 mM
+ PSC
5.5 mM
control
5.5 mM
+PSC
B) BC19 A) WT C) AdrR
Exposure time (h)
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
Figure 4 Percent survival of MCF7/WT (panel A), MCF7/BC19 (panel B), and MCF7/AdrR (panel C) cells following exposure to doxorubicin (1.8 or 5.5 mM) in
the presence or absence of 2 mM PSC833. Each point is the mean of 2 to 3 independent experimentsMonitoring inhibition of P-glycoprotein function 371
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DISCUSSION 
Early detection of MDR in the course of therapy is important in
cancer management but detection is made difficult by the multiple,
diverse mechanisms of MDR, which include additional transpor-
ters and alteration in topoisomerase II and glutathione-S-transferase
activity. Currently, Pgp is determined on biopsy samples and, aside
from leukaemia in which tumour cells are readily available, repeat
sampling is limited. Flow cytometry is a functional assay, while
other in vitro techniques such as quantitative PCR and
immunoblotting determine Pgp expression at molecular and
protein levels, respectively. However, it is not generally possible
to verify that Pgp function has been inhibited during modulator
studies and non-invasive detection of transporter-mediated resist-
ance remains an important goal. 
Flow cytometry provides quantitative information on Pgp func-
tion, on chemotherapeutic drug behaviour, and on effectiveness of
Pgp modulators (Kessel et al, 1991). Although these measures
make it possible to monitor onset of MDR and to make timely
modifications in treatment regimens, the need for biopsy samples
has limited the application of flow cytometry in most solid
tumours. Sestamibi imaging is a more recent approach to charac-
terization of Pgp status in tumours and its use is expanding. This
method provides a rapid, non-invasive, and repeatable assessment
of cellular and tumour Pgp function and in monitoring of Pgp
function modulation and response to chemotherapeutic treatment
(Del Vecchio et al, 1999; Hendrikse et al, 1999). 
In the present study, both doxorubicin and sestamibi shared
substrate properties for Pgp and our results show their similar
affinity for Pgp-transport function (Figures 2A, 2B, 3A and 3B).
The differences in results for the two drugs were a function of
other MDR factors that affected sestamibi uptake more than
doxorubicin. This is most evident in the incomplete reversal of
MDR function in the drug-selected MCF7/AdrR cell line that ex-
presses MDR due to collective factors (Figures 2C, 2D, 3C and 3D).
This study demonstrates that in cases in which MDR is due to Pgp
alone, as in the MCF7/BC19 cell line, complete reversal is
possible for both drugs. 
In drug-selected resistant cell lines, changes have been noted
in membrane, cytosolic, and nuclear proteins, drug conjugation
enzymes, cell morphology, metabolic function, mitochondrial
density, membrane potential charge, and sensitivity of target struc-
tures (Batist et al, 1986; Bradley et al, 1988; Cole et al, 1992;
Piwnica-Worms et al, 1993; Schneider et al, 1994; Sommers et al,
1994). Because sestamibi has been reported to be a substrate for
MRP as well as Pgp (Hendrikse et al, 1998), additional trans-
porters in MCF7/AdrR cells (possibly including MRP) may
have functioned as drug-efflux pumps for both drugs. MRP in
MCF7/AdrR cells was not measured in the present study, but
Benderra et al (2000) have recently shown that MCF7/AdrR cells
exhibit moderate levels of MRP1 gene by quantitative RT-PCR
and MRP protein by flow cytometry. In addition, other MDR
changes in MCF7/AdrR cells may have affected uptake and reten-
tion factors of sestamibi more than doxorubicin. In particular,
changes in mitochondrial density and membrane potential could
be important. 
Accumulation of doxorubicin is a function of free diffusion of
un-ionized drug which is extensively metabolized and retained in
cells by binding to DNA and plasma membrane phospholipids and
storage in intracellular compartments. Inhibition of Pgp function
by modulators and extensive metabolism with large number of
target sites for this drug may account for higher uptake of doxoru-
bicin in resistant cells relative to sestamibi. In MCF7/AdrR cells,
high levels of Pgp and a 45-fold increase in glutathione-
S-transferase (GST) have been reported (Batist et al, 1986;
Fairchild et al, 1990). This acquired ability of MCF7/AdrR cells to
conjugate more drug and produce large number of metabolites,
which can also be fluorescent (Takanashi and Bachur, 1976), could
account for the high levels of fluorescence detected in these cells
(Figures 3C and 3D). MDR1-gene-transfected MCF7/BC19 cells
that expressed resistance solely due to Pgp did not exhibit this
increased effect and behaved similarly to MCF7/WT cells in
presence of Pgp modulators (Figures 3A and 3B). 
For sestamibi, accumulation in cells is a function of free diffu-
sion based on electrical potentials across the plasma and mito-
chondrial membranes, with localization in the mitochondria by
electrostatic forces (Chiu et al, 1990). Davis et al (1985) studied
the cellular uptake properties of the lipophilic cationic fluorescent
dye rhodamine-123 and showed that carcinoma-derived cell lines
accumulated more rhodamine than normal epithelial cells. They
compared uptakes in the MCF7/WT cell line to a normal CV-1
epithelial cell line and showed that >85% of the difference in
uptake was a result of elevated mitochondrial membrane potentials
in MCF7 cells (Davis et al, 1985). Decreased uptake of sestamibi
in resistant cells has also been attributed to a lower membrane
potential and reduced mitochondrial density (Piwnica-Worms
et al, 1993). The high membrane potential in MCF7/WT cells and
lower potentials in resistant cells may together account for the
greater sestamibi uptake differences between the two cell types
and therefore the apparent higher sensitivity of sestamibi for
detecting MDR and its modulation, relative to doxorubicin. In the
present work, greater sensitivity could have been achieved by
substitution of rhodamine-123 for doxorubicin (Broxterman et al,
1996). Furthermore, as a permanently charged lipophilic cation,
rhodamine-123 behaviour might have been similar to sestamibi,
though it has been reported that rhodamine-123 is not transported
by MRP (Vergote et al, 1998). However, we felt it important to
evaluate a fluorescent drug rather than to find the best in vitro
probe. 
The lower membrane potentials may also help to explain our
inability to completely reverse drug resistance in MCF7/AdrR
cells similar to MCF7/WT and MCF7/BC19 cells. Supporting
evidence for this interpretation is also seen in results for
MCF7/BC19 cells. When Pgp function in MCF7/BC19 cells was
reversed by modulators, these cells achieved drug levels similar to
MCF7/WT cells, indicating that membrane potential changes were
not present in these cells. Thus Pgp alone affected their behaviour
and sestamibi results were different in MCF7/AdrR cells due to
other MDR factors. This result for sestamibi in MCF7/AdrR cells
was also similar to results from our laboratory with other cell lines
(Ballinger et al, 1995, 1997) and in other studies where high Pgp-
expressing MDR cell lines have shown only partial restoration of
radiolabelled drug accumulation in the presence of Pgp modula-
tors (Piwnica-Worms et al, 1993). Western blotting showed levels
of Pgp in MCF7/AdrR and MCF7/BC19 cells to be similar. 
Both GG918 and PSC833 were effective in restoring MCF7/WT
drug levels in the resistant cell-line variants. These potent second-
generation Pgp modulators are in clinical trials and only a few
studies have been published. The EC50 of both modulators was in
the mM dose range (GG918, 0.05 to 0.1 mM; PSC833, 1.0 to 2.0
mM) but GG918 was 10 to 20 times more potent than PSC833 for
doxorubicin uptake and 10 times more potent for sestamibi uptake372 T Muzzammil et al 
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(Figures 2 and 3). As well as the difference in potency, there was
a subtle difference in the shapes of the sestamibi accumulation
curves for the two modulators. With GG918 the tracer accumula-
tion is continuous over the 60-min time-course of the experiment
whereas for PSC833 there is a peak accumulation at about 30 min
followed by a slight decline (Figure 2). This can be attributed to
the different mechanism of action of the two modulators: GG918 is
an irreversible inhibitor while PSC833 is a competitive inhibitor
(Twentyman, 1988; Hyafil et al, 1993). This difference was not
evident with doxorubicin (Figure 3). 
Finally, the cytotoxicity study (Figure 4) showed that PSC833 at
the 2 mM dose level significantly enhanced the cytotoxic effect of
doxorubicin in both resistant cell lines. However, MCF7/AdrR cells
remained 2- to 5-fold more resistant, despite similar levels of doxoru-
bicin fluorescence (Figure 3); this could be due to additional meta-
bolic mechanisms of MDR and points out a limitation of doxorubicin
flow cytometry to predict sensitivity. Indeed, the sestamibi results
appear to offer more predictive value, though this experiment was
limited in scope and clearly much further study is required. 
Vergote et al (1998) measured the efflux kinetics of sestamibi
in cell lines K562 and GLC4, and their Pgp-and MRP-
overexpressing resistant variants K562/ADR and GLC4/ADR,
respectively. They concluded that sestamibi is transported with
similar efficiencies by Pgp and by MRP but that these efficiencies
are ~100 times lower than those reported for daunorubicin by the
same laboratory (Marbeuf-Gueye et al, 1998). The similarity in
efficiencies of efflux of sestamibi by Pgp and MRP may be coinci-
dental, since the parameter measured is a composite of affinity,
turnover number, and transporter number. The reported 100-fold
difference in efficiencies of sestamibi and daunorubicin transport
in the same cell lines may seem at odds with the conclusion of the
present work that sestamibi is a more sensitive indicator of Pgp
function than doxorubicin. However, the doxorubicin levels in the
resistant cell lines in the present work may be enhanced by non-
specific binding and the presence of fluorescent metabolites,
which would combine to reduce the apparent difference between
parental and resistant cell lines. 
Cayre et al (1999) studied the effects of single concentrations of
the Pgp modulators verapamil, PSC833, and S9788 on accumula-
tion of sestamibi and 3H-daunomycin in the human nasopharyn-
geal carcinoma cell line KB-3-1 and its doxorubicin-resistant
variant KB-A1. It was reported that only S9788 was able to reverse
the daunomycin accumulation deficit in KB-A1 cells and none of
the modulators enhanced sestamibi accumulation. These results
are puzzling, given that Crankshaw et al (1998) were able to show
complete reversal to wild-type behaviour of sestamibi in the 
KB-8-5 cell line, a colchicine-selected multidrug-resistant variant
of KB-3-1, and may represent co-expression of additional resis-
tance transporters. Thus, the results of Cayre et al (1999) in KB-
A1 cells may be analogous to those obtained in MCF7/AdrR cells
in the present work. 
In summary, both sestamibi accumulation and doxorubicin flow
cytometry techniques were able to detect MDR and its modulation,
and clearly distinguished sensitive from resistant MCF7 variants.
In MCF7/BC19 cells, Pgp-mediated efflux of sestamibi and
doxorubicin was completely reversible with Pgp modulators.
However, in MCF7/AdrR cells, reversal of the accumulation
deficit with modulators was complete for doxorubicin but only
partial for sestamibi. Sestamibi imaging, being non-invasive,
repeatable, and applicable to solid tumours, may play a role in
monitoring Pgp inhibition in the clinic. 
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